Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

被引：11
|
作者：
Tsai, Yi-Giien [1 ,2 ,3 ,4 ]
Liao, Pei-Fen [3 ,5 ]
Hsiao, Kai-Hung [6 ]
Wu, Hung-Ming [7 ]
Lin, Ching-Yuang [8 ]
Yang, Kuender D. [9 ,10 ]
机构：
[1] Changhua Christian Childrens Hosp, Dept Pediat, Changhua, Taiwan
[2] Kaohsiung Med Univ, Sch Med, Kaohsiung 807, Kaohsiung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taichung, Taiwan
[6] Changhua Christian Hosp, Dept Allergy Immunol & Rheumatol, Changhua, Taiwan
[7] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan
[8] China Med Univ Hosp, Childrens Hosp, Div Pediat Nephrol, Taichung, Taiwan
[9] MacKay Mem Hosp, Dept Pathol, New Taipei City, Taiwan
[10] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词：
systemic lupus erythematosus; lupus nephritis; regulatory T cells; interleukin-2; B regulatory cells; LOW-DOSE IL-2; B-CELLS; DISEASE-ACTIVITY; CD4(+); ACTIVATION; FOXP3; DIFFERENTIATION; SUPPRESSION; ASSOCIATION; CAPACITY;
D O I：
10.3389/fimmu.2023.1230264
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.
引用
收藏
页数：13
相关论文
共 50 条
  • [11] Systemic lupus erythematosus: pathogenesis and targeted therapy
    Su, Xu
    Yu, Hui
    Lei, Qingqiang
    Chen, Xuerui
    Tong, Yanli
    Zhang, Zhongyang
    Yang, Wenyong
    Guo, Yuanbiao
    Lin, Liangbin
    MOLECULAR BIOMEDICINE, 2024, 5 (01):
  • [12] Transcriptional repression of interleukin-2 in human systemic lupus erythematosus
    Katsiari, CG
    Tsokos, GC
    AUTOIMMUNITY REVIEWS, 2006, 5 (02) : 118 - 121
  • [13] Interleukin-2 and systemic lupus erythematosus - fifteen years later
    Crispin, JC
    Alcocer-Varela, J
    LUPUS, 1998, 7 (04) : 214 - 222
  • [14] Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus
    Akbarzadeh, Reza
    Riemekasten, Gabriela
    Humrich, Jens Y.
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (02) : 98 - 106
  • [15] Current and novel therapeutics in the treatment of systemic lupus erythematosus
    Yildirim-Toruner, Cagri
    Diamond, Betty
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : 303 - 312
  • [16] Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus
    He Hao
    Shingo Nakayamada
    Naoaki Ohkubo
    Kaoru Yamagata
    Mingzeng Zhang
    Yu Shan
    Shigeru Iwata
    Tong Zhang
    Yoshiya Tanaka
    Arthritis Research & Therapy, 23
  • [17] The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis
    Li, Wenli
    Deng, Chuiwen
    Yang, Hanbo
    Wang, Guochun
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [18] T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update
    Chen, Ping-Min
    Tsokos, George C.
    CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (02)
  • [19] A Disintegrin and metalloproteinase carves T cell abnormalities and pathogenesis in systemic lupus erythematosus
    Umeda, Masataka
    Satyam, Abhigyan
    Yoshida, Nobuya
    Kawakami, Atsushi
    CLINICAL IMMUNOLOGY, 2024, 262
  • [20] Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus
    Nakayamada, Shingo
    Iwata, Shigeru
    Tanaka, Yoshiya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2015, 18 (02) : 208 - 218
12345